NRIX
Nurix Therapeutics Inc
NASDAQ: NRIX · HEALTHCARE · BIOTECHNOLOGY
$16.70
+0.54% today
Updated 2026-04-30
Market cap
$1.72B
P/E ratio
—
P/S ratio
23.93x
EPS (TTM)
$-3.17
Dividend yield
—
52W range
$8 – $23
Volume
1.1M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+5.0
Quality
C+2.5
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$30.24
+81.08%
12-Month target
—
—
Intrinsic (DCF)
$24.33
Margin of safety
+33.79%
5 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 33.79% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-72.96M
- Revenue declining -66.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $38.63M | $76.99M | $54.55M | $83.98M | $71.78M |
| Net income | $-166.04M | $-143.95M | $-193.57M | $-264.46M | $-87.17M |
| EPS | — | — | — | — | $-3.17 |
| Free cash flow | $-172.05M | $-89.77M | $-181.86M | $-263.47M | $-72.96M |
| Profit margin | -429.87% | -186.98% | -354.85% | -314.90% | — |
Peer comparison
Smart narrative
Nurix Therapeutics Inc trades at $16.70. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $71.78M. Our DCF model estimates intrinsic value at $24.33.
Frequently asked questions
What is Nurix Therapeutics Inc's stock price?
Nurix Therapeutics Inc (NRIX) trades at $16.70.
Is Nurix Therapeutics Inc overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell). DCF value $24.33.
What is the price target of Nurix Therapeutics Inc (NRIX)?
The analyst target price is $30.24, representing +81.1% upside from the current price of $16.70.
What is the intrinsic value of Nurix Therapeutics Inc (NRIX)?
Based on our DCF model, intrinsic value is $24.33, a +33.8% margin of safety versus $16.70.
What is Nurix Therapeutics Inc's revenue?
TTM revenue is $71.78M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio23.93x
ROE-61.40%
Beta1.98
50D MA$15.81
200D MA$14.05
Shares out0.10B
Float0.10B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—